Showing results (121-130 of 141) with videos related to

Sort By:
Pageof 15
Clinical Pharmacology and Therapeutics|June 17, 2022
Ziritaxestat Drug-Drug Interaction with Oral Contraceptives: Role of SULT1E1 InhibitionEric Helmer, Negin Karimian, Karen Van Assche, et al.
The Journal of Dermatological Treatment|March 17, 2007
Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 yearEdwin J M Van Leent, Henry J C De Vries, Marie-Eve Ebelin, et al.
Clinical Pharmacokinetics|November 11, 2003
Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administrationGraham Scott, Stuart A Osborne, Gerard Greig, et al.
Clinical Pharmacokinetics|May 14, 2004
Pharmacokinetics of lumiracoxib in plasma and synovial fluidGraham Scott, Christiane Rordorf, Christine Reynolds, et al.
Developmental Psychobiology|March 24, 2026
Boosting Representation and Validity in Pediatric Electroencephalography Research: The Conceptualization, Development, and Implementation of the Curly Hair Specialist InitiativeMaría Isabella Natale Castillo, Monique Marsh, Charles Alexander Nelson, et al.
Epidemiology and Infection|December 12, 2022
High pathogenicity avian influenza: targeted active surveillance of wild birds to enable early detection of emerging disease threatsDaniel Wade, Adham Ashton-Butt, Graham Scott, et al.
Pediatric Dermatology|September 30, 2005
Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label studyDoris Staab, David Pariser, Alice B Gottlieb, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 16, 2004
Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated studyClare Atherton, John Jones, Brian McKaig, et al.
JOR Spine|November 15, 2024
Pharmacokinetics of PP353, a formulation of linezolid for intervertebral disc administration, in patients with chronic low back pain and Modic change Type 1: A first-in-human, Phase 1b, open-label, single-dose studyShiva S Tripathi, Robert Sneath, Aprajay Golash, et al.
Open Research Europe|July 3, 2026
The evolving study of political polarizationEmre Erdogan, Bernadette Nadya Jaworsky, Cláudia Álvares, et al.
Pageof 15